“What innovation policy on human health doesn’t need is Paul Clement, a brilliant but scientifically ill-informed Supreme Court advocate, speculating that the genus ‘retards science’.” Yes. How would he know? – Judge Paul Michel
The U.S. Supreme Court heard three separate claims today. amgen vs sanofia lawsuit that even Sanofi’s lawyers agreed to, if the court sided with Sanofi, or – as Sanofi’s lawyers and the Office of the Attorney General suggested – the court dismissed the case as extemporaneously granted. A patent containing a genus claim may be effectively canceled (digging).
The Court considers the following issues in this case:
Whether enablement is governed by 35 U.S.C. 112, the statutory requirement that the specification teach one of ordinary skill in the art to “make and use” the claimed invention, or whether the must be able to “reach its full scope”, i.e. cumulatively identify and produce all or nearly all embodiments of the invention without substantial “time and effort”.
Ramken: Shows why the amount of experimentation matters
MoloLamken’s Jeffrey Alan Lamken reiterated in support of Amgen: 2) If they identify it, indicate why it is important to the skilled craftsman. Since the statutes are about rationality and the attempts of skilled craftsmen to make and use inventions, theoretical far corners have never been shown to affect their ability to do so. ”
However, the judge seemed to have trouble grasping what the invention really was and expressed skepticism about the various numbers listed in the patent. (the “‘165 patent”) and No. 8,859,741 (the “‘741 patent”) “have the amino acid sequences of 26 antibodies that bind to the sweet spot of PCSK9 and thereby block PCSK9 from binding to the LDL receptor. The company generated “384 antibodies that ‘successfully’ blocked PCSK9 from binding to the LDL receptor, and 85 that blocked the interaction ‘more than 90%’.” What was claimed was in fact “millions of antibodies,” but his explanation didn’t end the line of question.
Amgen argues that the Federal Circuit’s requirement that a claim “reach its full scope” creates a high bar for asking irrelevant questions. It should be the quality of the experiment that matters, not the quantity. However, Lamken’s inability to provide a specific number of patentable antibodies appears to have unnerved some judges. Judge Thomas repeatedly challenged Lamken on this point, and Judge Kagan asked why Amgen didn’t actually make all of the nearly 400 antibodies that are said to block binding to the LDL receptor. . Lamken answers: I’m just looking for something that joins in the right place. ”
Clement: functional genus claims are terrible
In Sanofi’s case, Clement & Murphy’s Paul Clement appeared to have had an easy time on the overall question, but Prof. Mark Lemley’s Counsel Brief Claims Federal Circuit’s Approach Is Swept When asked to respond to Judge Kagan, he surprisingly granted Judge Kagan a valuable patent in the field:
Kagan: Mr. Clement, can you explain Professor Lemley? He seems to have a very strong view that these antibody genera claims are worthwhile. Yes, and the Federal Circuit’s test will wipe them out across the board. So why is Professor Lemley wrong in your view?
Clement: I think his idea that existing Federal Circuit precedent seeks to eliminate all genus claims is false…. There may be an inability to functionally claim genus, and that’s no one’s fault on some level. That’s how science works, and personally this is great because it allows different companies to independently develop different macromolecular therapies to combat the same disease. ”
KaganI heard you say he might be right about the Federal Circuit’s test invalidating most of these patents, and that’s fine.
Clement: “Truth has a way of leaking out. I mean, I say that because I think functional genus claims suck.
Clement pointed to Sir Gregory Winter’s Amicus brief, which argued that “Amgen’s purported ‘invention’ is merely the hindsight characterization of what has existed in nature.” Dr. Winter is a Nobel Prize-winning British molecular biologist, known for his work on the therapeutic use of monoclonal antibodies.However, in his rebuttal, Lamken called Winter’s brief “the functional equivalent of an expert report,” and that it was “very similar to Sanofi’s brief on appeals, so I am not convinced.” would like the court to look at our response brief, almost every answer Mr. Winter has [said]”
Clement also used the example of the process of making paint to illustrate how enablement works in his view. If his one step in the paint-making process is adding pigment for the desired color, Clement says:[w]Well, a seasoned craftsman could use that for a real roadmap, and they’d say they want Robin Egg Blue. If you want chartreuse instead, you can always produce it. ”
Also, although there may be an infinite number of colors that can be produced, the patent is not invalidated if the patent owner fails to produce all of them. Because it gives craftsmen the information they need to get what they want every time. ”
US Government: If Antibodies Are A Special Case, It’s The Call Of Congress, Not The Courts
U.S. Attorney General’s Office Colleen Shinsdak told the court that only the 26 antibodies specifically disclosed in Amgen’s patents were needed for scientists to go to the lab and make them. “The reason here is that it is possible for those skilled in the art to generate all the antibodies in the genus based on the clear fact that this is not a valid genus.” Because we didn’t provide the information that we should use it,” Sinzdak said. “It’s really easy.”
To help explain the law to anyone interested in this area of science, Justice Sotomayor said, as Clement previously joked, what the court will do if it doesn’t choose to “dive” into the case. Asked what he should say, Sinzdak replied that the government doesn’t believe the Federal Circuit said anything wrong, so the court can dig into the matter. To make each of the various embodiments you claim valid, they cannot be said to be “unimportant…”.
Judge Kavanaugh went on to ask Sinzdak whether it was important for the court to say it agreed with the Federal Circuit. If billions of dollars are at stake, this court says everyone will know it’s up to Congress to eliminate uncertainty about legal standards, along the lines of what you propose. ”
Sinzdak agrees with the court that it is beneficial, and that there is no need to “make a special antibody exception” to patent law as long as the judge agrees that antibody patents may simply be different. He pointed out that it is important to note that there is a parliament. .
In response, Lamken said the “cumulative effort” analysis articulated by the Federal Circuit is not appropriate as long as skilled craftsmen can “make what they want.” He warned the court that the lawsuit would have “incredible ramifications,” adding: No one can invest billions of dollars in it, even if it is relevant. ”
hot take
Below are the initial reactions to the discussion.
Judge Paul Michelle
Chief Judge, United States Court of Appeals for the Federal Circuit (retired)
“What innovation policy on human health doesn’t need is Paul Clement, a brilliant but scientifically ill-informed Supreme Court advocate, speculating that the genus ‘retards science’.” Yes. How would he know?
Regarding other companies “independently” developing “macromolecular therapies to combat the same disease,” he was again ill-informed, and this time about how patent law works. Companies can “design” patents, do so, and patent new inventions. This race to the top spawns many new therapies. Also, those whose designs are based on experimentation with patented molecules cannot be sued for infringement, but are protected under the Experimental Exception to Infringement. ”
Matthew Dowd
Dowd Bushel
“The apparent concerns about genus claims are misplaced and disappointing. Using genus claims for pioneering innovation allows innovators to make discoveries that open many new lines for future development.” It is possible that the person who originally invented seldom does all the experimentation and can create all the embodiments that follow from the groundbreaking innovation to the engineer practicing the claimed invention. Imposing standards that force innovators to spend more time generating rot data than is needed to teach is inconsistent with the price of the patent system. In an Amicus brief filed on behalf of an innovative food company that transforms protein products into organic protein products, for example, how the extensive Cohen-Boyer patents on recombinant DNA technology in the 1970s “demonstrate a pioneering underlying technology.” or” was explained. The technology is protected by extensive patent claims that have spurred innovations that change society. In another article, Professor Adam Mossoff and I elaborated on the innovation-enhancing role of genus claims. In short, the genus claim, even those with partial functional elements, Amgen Cases—advance useful art progress.
A full transcript of the discussion is here.
